Vitamin C for Immune Function — Colds, Pneumonia & Sepsis

Vitamin C and immune function is the most controversial of the four major benefit areas because the public expectation ("vitamin C prevents colds") does not match the trial data, while the trial finding that does hold ("regular supplementation cuts cold incidence by 50% in people under heavy physical stress") is almost unknown to the public. This deep-dive walks through the Hemilä Cochrane reviews trial-by-trial, the neutrophil and lymphocyte mechanisms that explain why ascorbate matters at all, the Marik metabolic-resuscitation sepsis protocol and the CITRIS-ALI follow-up, and a practical 1–2 g/day prevention dose versus 6–8 g/day treatment dose split with the bowel-tolerance principle for acute illness.

Table of Contents

  1. What Vitamin C Actually Does to Immune Cells
  2. Neutrophil Function: Chemotaxis, Phagocytosis, Respiratory Burst
  3. Lymphocytes, NK Cells, and Adaptive Immunity
  4. The Common Cold: What the Cochrane Review Actually Says
  5. The Athlete / Cold-Exposure Exception — 50% Reduction
  6. Pneumonia and Lower Respiratory Tract Infection
  7. Sepsis — Marik 2017, CITRIS-ALI, and the State of the Evidence
  8. Practical Dosing for Prevention vs Acute Treatment
  9. The Cathcart Bowel-Tolerance Principle
  10. Combinations: Zinc, Quercetin, Vitamin D, NAC
  11. Cautions Specific to Immune-Use Patients
  12. Key Research Papers
  13. Connections

What Vitamin C Actually Does to Immune Cells

The starting point for understanding ascorbate and immunity is a simple anatomical fact: neutrophils and lymphocytes contain Vitamin C at concentrations 50–100 times higher than plasma. The SVCT2 transporter actively pumps ascorbate into white cells against its gradient at significant metabolic cost. Evolution does not pay for that pump unless it matters.

Why it matters: every step of the innate immune response generates oxidative stress. The respiratory burst that kills phagocytosed bacteria, the cytokine cascade that recruits more neutrophils, the rapid clonal expansion of activated T-cells — all generate reactive oxygen species (ROS) inside the immune cell itself. Without intracellular antioxidant defense, the immune cell would damage itself faster than it could damage pathogens. Vitamin C, glutathione, and the antioxidant enzyme network constitute that defense.

When plasma ascorbate falls (smoking, sepsis, surgery, critical illness, chronic inflammation, marginal diet), intracellular leukocyte ascorbate falls too. Neutrophil chemotaxis slows. The respiratory burst weakens. T-cell proliferation in response to antigen contracts. The immune system is operating, but it is operating with degraded equipment. Restoring ascorbate restores function. None of this means megadosing healthy people improves their immunity beyond baseline — it means deficiency degrades immunity, and the threshold for deficiency for immune purposes is higher than the threshold for preventing scurvy.

Back to Table of Contents

Neutrophil Function: Chemotaxis, Phagocytosis, Respiratory Burst

Neutrophils are the most abundant white blood cell and the body's first cellular responder to bacterial infection. They live only hours after entering tissue, but during those hours they perform three sequential functions, each of which is ascorbate-dependent.

Chemotaxis is the directed migration of a neutrophil up a chemical gradient toward the source of infection. The gradient is set by complement fragments (C5a), bacterial peptides (formyl-methionyl peptides), and chemokines (IL-8). The neutrophil's cytoskeleton repeatedly polymerizes and depolymerizes actin to propel the cell. The Levy 1996 chronic granulomatous disease study showed that high-dose vitamin C corrected the defective neutrophil chemotaxis that characterizes that genetic disorder, demonstrating that ascorbate is a rate-limiting factor for chemotactic capacity.

Phagocytosis follows chemotaxis — the neutrophil engulfs the bacterium into a membrane-bound phagosome. Ascorbate supports phagocytic capacity by maintaining the cytoskeletal flexibility and the membrane fluidity required to extend pseudopods around the target.

Respiratory burst is the killing step. The NADPH oxidase complex in the phagosome membrane pumps electrons across the membrane, generating superoxide (O&sub2;−) in the phagosome lumen, which dismutates to hydrogen peroxide, which combines with chloride to form hypochlorous acid (bleach) — the actual bactericidal agent. This is a controlled oxidative burst aimed at the bacterium. The same chemistry would kill the neutrophil from inside if not for the high intracellular ascorbate and glutathione pools that mop up any leakage.

After the kill, neutrophils undergo apoptosis — programmed self-destruction — and are cleared by macrophages, resolving the inflammation. Vitamin C also supports this clearance step. Failure to clear apoptotic neutrophils is the mechanism behind chronic non-resolving inflammation in critical illness, and is the rationale for the Mohammed 2016 neutrophil extracellular trap (NET) regulation work showing ascorbate modulates NET formation.

Back to Table of Contents

Lymphocytes, NK Cells, and Adaptive Immunity

The lymphocyte side of the story is less dramatic but equally important. T-cells and B-cells also concentrate ascorbate via the SVCT2 transporter. When a naive T-cell encounters its cognate antigen on a dendritic cell, it begins to proliferate — doubling roughly every 6 hours for a week, eventually generating a clonal population millions of cells strong. That proliferation is metabolically extraordinary: glycolysis ramps up dramatically, and the resulting ROS load would block proliferation without intracellular antioxidant defense.

Ascorbate also supports cytotoxic T-cell killing of virus-infected targets, B-cell antibody production, and natural killer (NK) cell cytotoxicity against virally infected and malignant cells. The Carr and Maggini 2017 review in Nutrients compiles these findings into a single coherent picture: Vitamin C is required for normal adaptive immune function, deficiency degrades that function, and replacement restores it.

The interferon response is a particularly important downstream effect. Interferons are antiviral signaling proteins released by infected cells that put neighboring cells into an antiviral state. Ascorbate stimulates interferon production, which is part of why subjects with adequate ascorbate appear to handle viral infections better than deficient subjects independent of the more familiar cellular mechanisms.

Back to Table of Contents

The Common Cold: What the Cochrane Review Actually Says

The Hemilä and Chalker 2013 Cochrane review of vitamin C for the common cold is the definitive evidence synthesis. It pooled 29 randomized trials with over 11,000 participants. The findings are nuanced and frequently misreported in both directions.

Finding 1: Regular supplementation does NOT meaningfully prevent colds in the general population

Across the 29 trials, daily vitamin C supplementation (200 mg to several grams per day) did not reduce the number of cold episodes per year in the general adult population. The relative risk was approximately 0.97 — a 3% reduction that did not reach statistical significance. The pop-culture belief that "vitamin C prevents colds" is not supported by the trial data.

Finding 2: Regular supplementation modestly reduces cold DURATION

When colds do occur, regular daily supplementation reduces their duration by approximately 8% in adults and 14% in children. For a typical 7-day cold, this is roughly half a day to one day shorter. The effect is consistent across trials and statistically robust. Severity scores also improve modestly.

Finding 3: Therapeutic (not prophylactic) dosing during a cold does NOT consistently shorten it

The trials that gave vitamin C only after cold symptoms started, rather than as ongoing daily supplementation, generally failed to show benefit. This suggests the duration-reduction effect requires the body to be vitamin-C replete when the infection starts — tissue stores need to be saturated before the immune challenge, not after.

The honest summary

For a healthy adult with no specific risk factors, taking 200–1,000 mg of vitamin C daily produces a small reduction in cold duration if a cold occurs but does not measurably reduce how often colds occur. It is not a placebo — the effect is real and reproducible — but it is also not the dramatic protection that supplement marketing implies. The case for daily supplementation in this population rests on the other benefits (collagen, antioxidant, iron absorption, cardiovascular), not primarily on cold prevention.

Back to Table of Contents

The Athlete / Cold-Exposure Exception — 50% Reduction

The Cochrane review identified one subgroup in which regular vitamin C does dramatically reduce cold incidence: people under heavy physical stress, especially when combined with cold exposure. In the subgroup of marathon runners, soldiers in subarctic exercises, and skiers, regular vitamin C supplementation at 200–1,000 mg/day cut cold incidence by approximately 50%. This is a large, clinically meaningful effect that is statistically robust across multiple independent trials in different physical-stress populations.

The mechanism is plausible. Heavy physical exertion drives a transient post-exercise immunosuppression ("open window" theory) during which upper respiratory infections are more likely. Plasma ascorbate falls during exertion as it is consumed at the sites of exercise-induced oxidative stress. Cold exposure adds vasoconstriction and reduced mucosal immune surveillance to the picture. Pre-loading with vitamin C prevents the post-exercise plasma drop and keeps mucosal immunity functioning at baseline through the stress event.

The practical implication: athletes in heavy training, military personnel in field exercises, and anyone working outdoors in cold conditions for extended periods has a strong evidence-based case for 1–2 g/day prophylactic vitamin C during the period of physical stress. This is one of the cleanest evidence-base-to-practice translations in supplementation science.

Back to Table of Contents

Pneumonia and Lower Respiratory Tract Infection

The pneumonia evidence is more limited than the cold evidence but more clinically important because pneumonia mortality is non-trivial, especially in the elderly. The Hunt 1994 trial randomized 57 elderly hospitalized patients with acute bronchitis or pneumonia to vitamin C 200 mg/day or placebo. The vitamin C group had significantly better clinical scores and faster recovery, with the largest effect in the most severely ill subgroup. The trial was small but methodologically clean and is the clearest randomized evidence in this setting.

Multiple subsequent observational and smaller interventional studies have shown similar patterns: low baseline plasma ascorbate is associated with increased pneumonia incidence and severity; supplementation appears to improve outcomes most in subjects who were deficient at baseline; benefit is most consistent in elderly and institutionalized populations where deficiency is common. The Bharara 2016 case series of IV vitamin C in viral ARDS is suggestive but uncontrolled.

The Hemilä and de Man 2021 review of vitamin C in ICU patients pulled together the broader critical-care evidence and concluded that low plasma ascorbate is essentially universal in ICU patients with severe infection, that the drop is rapid (days), and that replacement is likely beneficial but the optimal dose, route, and timing remain open research questions.

Back to Table of Contents

Sepsis — Marik 2017, CITRIS-ALI, and the State of the Evidence

The sepsis story is the highest-profile recent chapter in vitamin C clinical research, and it has been a roller coaster.

Marik 2017 (Chest) — the spark

Paul Marik, a critical-care intensivist at Eastern Virginia Medical School, published a before-after retrospective case series in Chest: 47 septic-shock patients treated with IV vitamin C (1.5 g every 6 hours) + IV thiamine (200 mg every 12 hours) + IV hydrocortisone (50 mg every 6 hours), compared to a historical control cohort of 47 septic-shock patients treated with standard care. Hospital mortality dropped from 40% in controls to 8.5% in the treatment group. The effect size was extraordinary, and despite the methodological weaknesses of a before-after design with historical controls, the paper triggered widespread interest and rapid uptake of the "HAT protocol" (hydrocortisone, ascorbate, thiamine) in critical-care units worldwide.

The subsequent randomized trials — mixed

Multiple randomized controlled trials followed: VITAMINS (2019), ACTS (2020), VICTAS (2021), LOVIT (2022). They have produced mixed results. Most have shown no mortality benefit. Some have shown subgroup signals (faster ICU resolution of shock, reduced vasopressor requirements). LOVIT (Lamontagne 2022, NEJM) found a small increase in death or persistent organ dysfunction in the vitamin C arm, prompting many critical care units to back off the HAT protocol.

CITRIS-ALI — the cleaner signal

The CITRIS-ALI trial (Fowler 2019, JAMA) tested IV vitamin C alone (not the HAT cocktail) in sepsis with acute respiratory distress syndrome. The primary outcomes (modified SOFA score, CRP, thrombomodulin) did not differ between groups. But a secondary analysis showed substantially lower 28-day mortality in the vitamin C arm (29.8% vs 46.3%, p=0.03) and more ICU-free days. The signal was buried under negative primary outcomes but is suggestive enough that follow-up trials are ongoing.

Where the evidence stands today

For sepsis, IV vitamin C is no longer routinely recommended as monotherapy or as part of the original HAT cocktail. But the underlying biology — that septic patients are essentially uniformly ascorbate-depleted, that this depletion impairs vasopressor responsiveness and endothelial function, and that physiological replacement is biologically reasonable — remains valid. Most experts now recommend physiological-dose replacement (1.5 g IV daily) in septic ICU patients with documented low plasma ascorbate, rather than the pharmacological-dose HAT protocol. This is not a settled question.

Back to Table of Contents

Practical Dosing for Prevention vs Acute Treatment

Daily prevention (general adult)

Heavy physical stress (athlete, soldier, cold-exposure)

Acute cold or flu treatment

Hospital / ICU clinical setting

Back to Table of Contents

The Cathcart Bowel-Tolerance Principle

Dr. Robert Cathcart, a California physician, published the bowel-tolerance principle in 1981 in Medical Hypotheses. The observation: when a person is well, the dose of oral vitamin C that produces loose stools is in the range of 4–15 g/day. When the same person develops a viral infection, the bowel-tolerance dose rises — sometimes to 30–100 g/day during severe acute illness — reflecting the dramatically increased systemic consumption of ascorbate by the inflamed and infected tissues. Vitamin C is effectively being "absorbed away" before it reaches the colon where it would otherwise cause osmotic diarrhea.

Cathcart's clinical method: start with a familiar dose (say, 1 g every hour), increase until loose stools develop, then back off by 25–50% to the highest tolerated dose. Maintain that dose until symptoms resolve, then taper. The point is not the megadose itself but the use of GI tolerance as a personalized biofeedback signal that titrates dose to current physiological need.

The principle is empirically reasonable and the safety record at short-term high-dose oral ascorbate is excellent in subjects without G6PD deficiency, hemochromatosis, or kidney stone history. It has not been formally validated in randomized trials and is an example of clinical practice that runs ahead of evidence-base standards. Used as a short-term acute-illness intervention rather than a chronic protocol, it is low-risk.

Back to Table of Contents

Combinations: Zinc, Quercetin, Vitamin D, NAC

Back to Table of Contents

Cautions Specific to Immune-Use Patients

Back to Table of Contents

Key Research Papers

  1. Hemilä H, Chalker E (2013). Vitamin C for preventing and treating the common cold. Cochrane Database of Systematic Reviews. — PubMed
  2. Hemilä H (1996). Vitamin C and common-cold incidence under heavy physical stress. Int J Sports Med. — PubMed
  3. Marik PE et al. (2017). Hydrocortisone, vitamin C, and thiamine for the treatment of severe sepsis and septic shock. Chest. — PubMed
  4. Fowler AA et al. (2019). CITRIS-ALI: Effect of vitamin C infusion on organ failure in sepsis and ARDS. JAMA. — PubMed
  5. Lamontagne F et al. (2022). LOVIT trial — intravenous vitamin C in adults with sepsis in the intensive care unit. NEJM. — PubMed
  6. Carr AC, Maggini S (2017). Vitamin C and immune function. Nutrients. — PubMed
  7. Hunt C et al. (1994). The clinical effects of vitamin C supplementation in elderly hospitalised patients with acute respiratory infections. Int J Vitam Nutr Res. — PubMed
  8. Levy R et al. (1996). Vitamin C corrects neutrophil chemotactic defect in chronic granulomatous disease. Blood. — PubMed
  9. Cathcart RF (1981). Vitamin C, titrating to bowel tolerance, anascorbemia, and acute induced scurvy. Med Hypotheses. — PubMed
  10. Wintergerst ES, Maggini S, Hornig DH (2006). Immune-enhancing role of vitamin C and zinc. Ann Nutr Metab. — PubMed
  11. Hemilä H, de Man AME (2021). Vitamin C in ICU patients with COVID-19 and other severe infections. Front Med. — PubMed
  12. Mohammed BM et al. (2016). Vitamin C: a novel regulator of neutrophil extracellular trap formation. Nutrients. — PubMed

PubMed Topic Searches

Back to Table of Contents

Connections

Back to Table of Contents